Could psychedelics simultaneously treat chronic pain and depression?
Through the PURM internship program, undergraduate Ahmad Hammo is spending the summer alongside Joseph Cichon in the Perelman School of Medicine investigating the potential for psilocybin to treat chronic neuropathic pain.
Ahmad Hammo, a rising third-year student in bioengineering, is investigating psilocybin’s potential as a therapy for chronic pain and the depression that often accompanies it.
Ongoing clinical trials have demonstrated that psychedelics like psilocybin and LSD can have rapid and long-lived antidepressant and anti-anxiety effects. A related clinical problem is chronic pain, which is notoriously difficult to treat and often associated with depression and anxiety.
This summer, Ahmad Hammo, a rising third-year student in bioengineering in the School of Engineering and Applied Science, is conducting a pilot study to explore psilocybin’s potential as a therapy for chronic pain and the depression that often accompanies it.
“There’s a strong correlation between chronic pain and depression, so I’m looking at how a psychedelic might be used for treating both of these things simultaneously,” says Hammo, who is originally from Amman, Jordan.
Hammo’s project focuses on neuropathic pain, pain associated with nerve damage. Like other forms of chronic pain, most experts believe that chronic neuropathic pain is stored in the brain.
“Neuropathic pain can lead to a centralized pain syndrome where the pain is still being processed in the brain,” Cichon says. “It’s as if there’s a loop that keeps playing over and over again, and this chronic form is completely divorced from that initial injury.”
Cichon’s lab has previously investigated how other psychedelic compounds like ketamine change the brain, but this is the first time someone in his group has worked on psilocybin or attempted to use a psychedelic to address chronic pain. “What makes psychedelics so exciting is that maybe this is sort of the sledgehammer or tool that the brain needs to be shaken up so it can land back down into a normal state,” Cichon says.
Hammo says he was eager to dive into the project, which differs somewhat from his usual bioengineering coursework, for the opportunity to explore one of his other interests: medicine.
“I’m a bioengineering major, but at the same time I’m very interested in health care and medicine,” he says. “I’m on the pre-med track, so I wanted to work on a project that was more involved in health care.”
Hammo and Cichon are testing whether psilocybin can alleviate symptoms of chronic pain and depression in an animal model by comparing mouse behavior and mood before and after they receive psilocybin. They’re also using brain-imaging techniques to visualize psilocybin’s effects on individual cells and neural pathways within the brain. The preliminary results look promising, Hammo says, but there’s a lot more testing to do.
Research aside, Hammo has relished the opportunity to learn more about the world of neuroscience through conversations with Cichon and by shadowing him in the operating room during neurosurgery cases.
“Every single thing that we do here is new to me; it’s been a very enriching experience,” Hammo says. “We often just chat for a whole hour or an hour and a half about science, and it’s so cool to learn about these things and how they’re applied in humans. It makes you feel like you’re doing something bigger than what you think you can do as an undergrad.”
Hammo and Cichon say the internship has been a rewarding experience for them both, and they are already planning to continue working together after the summer ends.
“What’s so good about this lab in particular is that undergraduates are able to lead their own projects,” Hammo says. “You’re involved from A to Z and doing everything yourself.”
“This interaction has been the highlight of my summer,” says Cichon. “Hammo is one of my first undergrads to have no neuroscience background and at the same time he’s pioneered a new direction in my laboratory. It was an absolute win-win.”
When the Schuylkill swallowed the city: Lessons from Hurricane Ida’s historic flood
New Penn research shows that Hurricane Ida wasn’t a once-in-a-century anomaly but a preview of how climate change, urbanization, and aging infrastructure are rewriting flood risk.
The Fed explained: What it does and why it matters
Former Philadelphia Fed President Patrick Harker and financial historian Peter Conti-Brown, both Wharton professors, unpack the central bank’s origins, its unusual structure, and the quiet ways it shapes the economy
How population changes are impacting primary education worldwide
Research from Penn sociologist Emily Hannum and colleagues reveals regional trends in whether school-age populations are increasing, plateauing, or decreasing—and shows how different countries are responding.
A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.
Fighting oral cancer with bioengineered chewing gum
Research led by Penn Dental’s Henry Daniell shows that antiviral and antibacterial chewing gums reduce the levels of three microbes linked to worse outcomes in oral cancers, paving the way for more effective and affordable therapies.
